EU/3/11/912: Orphan designation for the prevention of graft loss in pancreatic islet transplantation



On 27 September 2011, orphan designation (EU/3/11/912 was granted by the European Commission to Dompé S.p.A., Itlay, for reparixin for the prevention of graft rejection in pancreatic islet transplantation.

The sponsorship was transferred to Dompé farmaceutici s.p.a., Italy, in March 2015.

For a list of the administrative updates to this public summary of opinion please refer to the PDF document below.

Key facts

Active substance
Intended use
Prevention of graft loss in pancreatic islet transplantation
Orphan designation status
EU designation number
Date of designation
Dompé farmaceutici s.p.a.
Via Santa Lucia 6
20122 Milano
Tel. +39 02 58 38 35 59
Fax +39 02 36 02 69 27

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating